Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P15104: Variant p.Arg341Cys

Glutamine synthetase
Gene: GLUL
Feedback?
Variant information Variant position: help 341 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Cysteine (C) at position 341 (R341C, p.Arg341Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In GLND; reduced glutamine synthetase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 341 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 373 The length of the canonical sequence.
Location on the sequence: help ASIRIPRTVGQEKKGYFEDR R PSANCDPFSVTEALIRTCLL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         ASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRT-CLL

                              ASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRT-CL

Mouse                         ASIRIPRTVGQEKKGYFEDRRPSANCDPYAVTEAIVRT-CL

Rat                           ASIRIPRIVGQEKKGYFEDRRPSANCDPYAVTEAIVRT-CL

Pig                           ASIRIPRTGGQEKKGYFEDRRPSANCDPFAVTEALIRT-CL

Bovine                        ASIRIPRTVGQEKKGYFEDRRPSANCDPFAVTEALIRT-CL

Chicken                       ASIRIPRNVGHEKKGYFEDRGPSANCDPYAVTEALVRT-CL

Xenopus laevis                ASIRIPRQVGQEGYGYFEDRRPAANCDPYAVTEALVRT-TI

Caenorhabditis elegans        CSIRIPRQVAAERKGYLEDRRPSSNCDPYQVTAMIAQS-IL

Baker's yeast                 SSIRIPRSVAKEGYGYFEDRRPASNIDPYLVTGIMCETVCG

Fission yeast                 ASVRIPRSVAMNGCGYFEDRRPASSIDPYLVTGIITET-M-
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 373 Glutamine synthetase
Domain 113 – 373 GS catalytic
Binding site 324 – 324
Binding site 338 – 338
Binding site 340 – 340
Modified residue 343 – 343 Phosphoserine
Mutagenesis 324 – 324 R -> A. Decreases ribosomal 40S subunit synthesis. Loss of nucleolar location of BYSL.



Literature citations
Congenital glutamine deficiency with glutamine synthetase mutations.
Haeberle J.; Goerg B.; Rutsch F.; Schmidt E.; Toutain A.; Benoist J.-F.; Gelot A.; Suc A.-L.; Hoehne W.; Schliess F.; Haeussinger D.; Koch H.G.;
N. Engl. J. Med. 353:1926-1933(2005)
Cited for: VARIANTS GLND CYS-324 AND CYS-341; CHARACTERIZATION OF VARIANTS GLND CYS-324 AND CYS-341; FUNCTION; CATALYTIC ACTIVITY; INVOLVEMENT IN GLND; Clustered de novo start-loss variants in GLUL result in a developmental and epileptic encephalopathy via stabilization of glutamine synthetase.
Jones A.G.; Aquilino M.; Tinker R.J.; Duncan L.; Jenkins Z.; Carvill G.L.; DeWard S.J.; Grange D.K.; Hajianpour M.J.; Halliday B.J.; Holder-Espinasse M.; Horvath J.; Maitz S.; Nigro V.; Morleo M.; Paul V.; Spencer C.; Esterhuizen A.I.; Polster T.; Spano A.; Gomez-Lozano I.; Kumar A.; Poke G.; Phillips J.A. III; Underhill H.R.; Gimenez G.; Namba T.; Robertson S.P.;
Am. J. Hum. Genet. 111:729-741(2024)
Cited for: CHARACTERIZATION OF VARIANTS GLND CYS-324 AND CYS-341; MUTAGENESIS OF 1-MET--TYR-17; INDUCTION; INVOLVEMENT IN DEE116;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.